Cell Therapeutics ($CTIC) appeals FDA decision on pixantrone

Cell Therapeutics said today that, as planned, it's submitted a formal appeal to the FDA regarding the agency's decision to reject pixantrone, an experimental treatment for relapsed/refractory aggressive non-Hodgkin's lymphoma. Release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.